

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:[V11W](#)^{0.12%}_{cons:21,603}•[I13V](#)^{100%}_{cons:27,852}•[G16A](#)^{10%}_{cons:28,535}•[E35D](#)^{10%}_{cons:42,098}•[M36I](#)^{100%}_{cons:42,081}•[R41K](#)^{10%}_{cons:43,028}•[K43R](#)^{10%}_{cons:43,080}•[R57K](#)^{10%}_{cons:42,238}•[H69K](#)^{10%}_{cons:40,433}•[L89M](#)^{10%}_{cons:39,360}

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible

PR comments

Other

- V11W/L** are relatively non-polymorphic accessory mutation selected in persons receiving DRV. V11L is a nonpolymorphic PI-selected mutation associated with reduced in vitro DRV susceptibility when it occurs in combination with other PI-resistance mutations.

No drug resistance mutations were found for PI.

NRTI Mutations:[M184V](#)^{10%}_{cons:28,438}

NNRTI Mutations:[K103N](#)^{10%}_{cons:15,682}

RT Other Mutations:[P4Q](#)^{10%}_{cons:33,708}•[K11T](#)^{10%}_{cons:30,365}•[K20R](#)^{10%}_{cons:22,234}•[V21I](#)^{10%}_{cons:22,287}•[E28K](#)^{10%}_{cons:20,001}•[K32E](#)^{10%}_{cons:23,832}•[V35T](#)^{10%}_{cons:29,345}•[T39N](#)^{10%}_{cons:28,126}•[V60I](#)^{10%}_{cons:14,811}•[K101A](#)^{1%}_{cons:8,30%}•[K122E](#)^{10%}_{cons:30,264}•[D123N](#)^{10%}_{cons:10,264}•[I135T](#)^{10%}_{cons:11,880}•[K173A](#)^{10%}_{cons:26,432}•[Q174K](#)^{10%}_{cons:26,433}•[T200A](#)^{10%}_{cons:30,514}•[Q207E](#)^{10%}_{cons:30,008}•[R211K](#)^{100%}_{cons:29,512}•[V243Q](#)^{10%}_{cons:27,466}•[E248N](#)^{10%}_{cons:27,143}•[D250E](#)^{10%}_{cons:26,808}•[S251SC](#)^{0.14%}_{cons:26,363}•[A272P](#)^{10%}_{cons:23,000}•[K281R](#)^{10%}_{cons:25,130}•[T286A](#)^{10%}_{cons:28,788}•[E291D](#)^{10%}_{cons:17,806}•[I293V](#)^{10%}_{cons:17,008}

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Low-Level Resistance	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	High-Level Resistance
emtricitabine (FTC)	High-Level Resistance	etravirine (ETR)	Susceptible
lamivudine (3TC)	High-Level Resistance	nevirapine (NVP)	High-Level Resistance
tenofovir (TDF)	Susceptible	rilpivirine (RPV)	Susceptible

RT comments

NRTI

- M184V/I** cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). **M184V/I** are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

NNRTI

- K103N** is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.

Other

- K101N/A/T** are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance.

Drug resistance mutation scores of NRTI:

Download CSV

Rule	ABC ⬆	AZT ⬆	FTC ⬆	3TC ⬆	TDF ⬆
M184V	15	-10	60	60	-10

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR ⬆	EFV ⬆	ETR ⬆	NVP ⬆	RPV ⬆
K103N	0	60	0	60	0